

Supplementary File 2. Links to the PBAC submissions described in Table 6

Health consumer organisation	Top 3 companies	Related drugs under PBAC review 2013-2016	Links to the PBAC submissions
Macular Disease Foundation Australia	Bayer	Aflibercept	• Aflibercept, injection, 4 mg/0.1 mL, Eylea® • Aflibercept, 2 mg/0.05 mL injection, 1 x 0.05 mL vial and 2 mg/0.05 mL injection, 1 x 0.05 mL syringe, Eylea® • Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® (DME) • Aflibercept; 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea® (CRVO) • Aflibercept: 4 mg/0.1 mL injection, 1 x 0.1 mL vial, 4 mg/0.1 mL injection, 1 x 0.09 mL syringe; Eylea®
	Novartis	Ranibizumab	• RANIBIZUMAB, solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis® • RANIBIZUMAB (DME), solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis® • RANIBIZUMAB (RVO), solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis® • Ranibizumab, solution for intravitreal injection, 2.3 mg in 0.23 mL, Lucentis®, Novartis Pharmaceuticals Australia Pty Ltd * • Ranibizumab, 2.3 mg/0.23 mL injection, 0.23 mL vial, Lucentis® (DME) • RANIBIZUMAB (RVO), 2.3 mg/0.23 mL injection, 0.23 mL vial, Lucentis®, Novartis Pharmaceuticals Australia Pty Ltd
	Mylan	-	-
	Boehringer Ingelheim	Afatinib	• Afatinib, tablets, 20 mg, 30 mg, 40 mg and 50 mg, (as dimaleate) Giotrif® (first line) • Afatinib, tablets, 20 mg, 30 mg, 40 mg and 50 mg, (as dimaleate) Giotrif® (second / third line) • Afatinib dimaleate; 20 mg tablet, 28; 30 mg tablet, 28; 40 mg tablet, 28; 50 mg tablet, 28; Giotrif®
		Nintedanib	• Nintedanib, 100 mg capsule, 60; 150 mg capsule, 60; Ofev® • Nintedanib: 100 mg capsule, 60, 150 mg capsule, 60, Ofev®

Lung Foundation Australia†		Olodaterol	Olodaterol, 2.5 microgram/actuation inhalation: solution for, 60 actuations, Striverdi® Respimat® Boehringer Ingelheim Pty Ltd
		Tiotropium with olodaterol	Tiotropium bromide with olodaterol hydrochloride; tiotropium 2.5 microgram/actuation + olodaterol 2.5 microgram/actuation inhalation: solution for, 60 actuations; Spiolto® Respimat® Tiotropium with olodaterol: Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses; Spiolto® Respimat®
	Roche	Erlotinib	Erlotinib, tablets, 25 mg, 100 mg, 150 mg (as hydrochloride), Tarceva® Erlotinib, 25 mg tablet, 30, 100 mg tablet, 30 and 150 mg tablet, 30, Tarceva®, Roche Products Pty Limited *
	GSK	Fluticasone and vilanterol	Fluticasone Furoate and Vilanterol Trifenatate, dry powder inhaler, fluticasone furoate 100 microgram/actuation + vilanterol trifenatate 25 microgram/actuation, Breo® Ellipta®, GlaxoSmithKline Australia Pty Ltd (COPD) * Fluticasone Furoate and Vilanterol Trifenatate, dry powder inhaler, fluticasone furoate 100 microgram/actuation + vilanterol (as trifenatate) 25 microgram/actuation, Breo® Ellipta®
		Umeclidinium	Umeclidinium (as Bromide), 62.5 microgram/actuation, inhalation: powder for, 30 actuations, Incruse® Ellipta®
		Umeclidinium with vilanterol	Umeclidinium Bromide and Vilanterol Trifenatate, umeclidinium bromide 62.5 microgram/actuation + vilanterol trifenatate 25 microgram/actuation inhalation: powder for, Anoro™ Ellipta®, GlaxoSmithKline Australia Pty Ltd * Umeclidinium Bromide with Vilanterol Trifenatate, umeclidinium (as bromide) 62.5 microgram/actuation + vilanterol (as trifenatate) 25 microgram/actuation inhalation: powder for, 30 actuations, Anoro® Ellipta® Umeclidinium + vilanterol; umeclidinium (as bromide) 62.5 microgram/actuation + vilanterol (as trifenatate) 25 microgram/actuation, inhalation: powder for, 30 actuations; Anoro® Ellipta®
MS Australia	Sanofi	Teriflunomide	Teriflunomide, tablet, 14 mg, Aubagio ® Teriflunomide: Tablet 14 mg; Aubagio®
	Bio-CSL	Glatiramer acetate	-

	Bayer	-	-
Arthritis Australia	Janssen	Golimumab, Infliximab,	Golimumab, 50 mg/0.5 mL injection, 1x 0.5 mL, syringe Simponi®; Infliximab, 100 mg injection, 1x 100 mg vial, Remicade®; Ustekinumab 45 mg/0.5 ml injection, 1x 0.5 ml vial, Stelara®; Janssen-Cilag Pty Ltd
		Ustekinumab	Ustekinumab; 45 mg/0.5 mL injection, 1 x 0.5 mL vial; Stelara® Ustekinumab; 45 mg/0.5 mL injection vial, 1; Stelara® Ustekinumab: 45 mg/0.5 mL injection, 1 x 0.5 mL vial, Stelara®
	Roche	Tocilizumab	TOCILIZUMAB, concentrate for injection, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra® Tocilizumab, solution for I.V. infusion, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra®
	UCB	Certolizumab	Certolizumab pegol; 200 mg/mL injection, 2 x 1 mL syringes; Cimzia®
Rare Cancers Australia‡	Janssen	Bendamustine	Bendamustine Hydrochloride; 25 mg injection: powder for, 1 vial, 100 mg injection: powder for, 1 vial; Ribomustin® Bendamustine; powder for injection 100 mg vial, 1; powder for injection 25 mg vial, 1; Ribomustin®
		Bortezomib	-
		Ibrutinib	Ibrutinib; 140 mg capsules, 90; Imbruvica® Ibrutinib: oral capsule, 140 mg, Imbruvica® Ibrutinib: 140 mg capsules, 90, Imbruvica® Ibrutinib (CLL/SLL): 140 mg capsules, 90; Imbruvica® Ibrutinib (MCL): Capsule 140 mg; Imbruvica®
	Pfizer	Axitinib	AXITINIB, tablet, 1 mg and 5 mg, Inlyta® Axitinib; tablets, 1 mg & 5 mg; Inlyta®
		Sunitinib	Sunitinib, capsule, 12.5 mg, 25 mg, 50 mg (as malate), Sutent®

	Roche	Capecitabine)	Capecitabine; megestrol; toremifene; vinorelbine
		Obinutuzumab	• Obinutuzumab, solution for IV infusion, 1000 mg/40 mL, Gazyva®, Roche Products Pty Ltd • Obinutuzumab; 1 g/40 mL injection, 40 mL vial; Gazyva® • Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva®
		Rituximab	• Rituximab, solution for IV infusion, 100 mg in 10 mL, 500 mg in 50 mL, Mabthera® • Rituximab; 500 mg/50 mL injection: 1 x 50 mL vial; MabThera® • Rituximab; injection for infusion; 500mg/50mL; Mabthera®
		Trastuzumab	Trastuzumab; powder for I.V. infusion, 60 mg vial,1; powder for I.V. infusion, 150 mg vial, 1; Herceptin®
		Vismodegib	• Vismodegib: 150 mg capsule, 28, Erivedge® • Vismodegib: Capsule 150 mg; Erivedge®

†For Lung Foundation Australia, we included drugs for COPD, lung cancer, rare lung cancer as these are the three main conditions listed in the “Patient support” area of the organisation’s website. (<https://lungfoundation.com.au/patient-support/> Accessed in March 2018)

‡For Rare cancers, we included all cancer drugs except those for breast, prostate, bowel, lung and melanoma as these are listed on the website of the health consumer organisation as common cancers and therefore not the focus of the work of the group. (<https://www.rarecancers.org.au/page/15/our-mission>, Accessed in March 2018)